Tempus funding, news & analysis

Unlock Full Access Sign In

Home > Companies > Tempus

Tempus

IPO on NASDAQ: TEM

Software and genomic testing tools for personalized treatment and clinical trial matching

#biotechnology

Funding

$1.16B

2024

Details

Headquarters

Chicago, United States

Website

Milestones

FOUNDING YEAR

2015

IPO

June 2024

Listed In

#biotechnology

Date	Event	Valuation	Amount	Price	Status
Jul 2026	Direct Sale Sources Under the terms of the agreement Tempus will acquire all outstanding shares of Personalis not already owned by Tempus at a price of $16.25 per common share, representing a 6% premium to Friday’s closi investors.tempus.com Results in a total transaction value of $1.7Bn ( $1.5Bn net of Tempus’ existing ownership interest) Consideration • Consideration will be structured as a combination of TEM stock and up to 50% cash at investors.tempus.com	$1.5B	$1.7B	$16.25	Announced
Unlock Tempus data Sign up for data access
Nov 2025	Tender Offer	—	—	—	Announced
Jun 2024	Growth	—	—	—	Closed
Apr 2024	Series G	—	—	—	Closed
Apr 2022	Series G	—	—	—	Closed
Dec 2020	Series G	—	—	—	Closed
Mar 2020	Series G	—	—	—	Closed
May 2019	Series F	—	—	—	Closed
Aug 2018	Series E	—	—	—	Closed
Mar 2018	Series D	—	—	—	Closed
Sep 2017	Series C	—	—	—	Closed
Apr 2017	Series B-2	—	—	—	Closed
Sep 2015	Series A	—	—	—	Closed
Aug 2015	Series A	—	—	—	Closed

Details

Headquarters

Chicago, United States

Website

Milestones

FOUNDING YEAR

2015

IPO

June 2024

Listed In

#biotechnology